SLC46A3

Summary

SLC46A3 (solute carrier family 46 member 3, HGNC:27501) is a protein-coding gene on chromosome 13q12.3, encoding Lysosomal proton-coupled steroid conjugate and bile acid symporter SLC46A3 (Q7Z3Q1). Lysosomal proton-coupled steroid conjugate and bile acid transporter.

The protein encoded by this gene is a member of a transmembrane protein family that transports small molecules across membranes. The encoded protein has been found in lysosomal membranes, where it can transport catabolites from the lysosomes to the cytoplasm. This protein has been shown to be an effective transporter of the cytotoxic drug maytansine, which is used in antibody-based targeting of cancer cells.

Source: NCBI Gene 283537 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 74 total
• MANE Select transcript: NM_181785

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:27501
Approved symbol	SLC46A3
Name	solute carrier family 46 member 3
Location	13q12.3
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp686A1775, FLJ42613
Ensembl gene	ENSG00000139508
Ensembl biotype	protein_coding
OMIM	616764
Entrez	283537

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 9 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000266943, ENST00000380814, ENST00000475385, ENST00000878130, ENST00000878131, ENST00000878132, ENST00000878133, ENST00000878134, ENST00000949432, ENST00000949433

RefSeq mRNA: 3 — MANE Select: NM_181785 NM_001135919, NM_001347960, NM_181785

CCDS: CCDS45021, CCDS9332

Canonical transcript exons

ENST00000266943 — 6 exons

Exon	Start	End
ENSE00001628966	28712680	28713550
ENSE00001643871	28710760	28710843
ENSE00001687712	28703943	28704099
ENSE00001931353	28700080	28701581
ENSE00002306880	28717810	28718022
ENSE00003902607	28718496	28718970

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 97.29.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.7105 / max 356.7856, expressed in 1439 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
136588	8.8163	1308
136584	2.2855	845
136583	0.1327	48
136589	0.1274	54
136587	0.0918	37
136586	0.0828	22
136585	0.0750	23
136581	0.0558	23
136582	0.0432	12

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	97.29	gold quality
adrenal tissue	UBERON:0018303	94.56	gold quality
jejunal mucosa	UBERON:0000399	94.21	gold quality
choroid plexus epithelium	UBERON:0003911	94.21	gold quality
right lobe of liver	UBERON:0001114	93.79	gold quality
duodenum	UBERON:0002114	93.26	gold quality
mucosa of transverse colon	UBERON:0004991	91.79	gold quality
liver	UBERON:0002107	91.20	gold quality
small intestine Peyer’s patch	UBERON:0003454	90.51	gold quality
gall bladder	UBERON:0002110	90.41	gold quality
renal glomerulus	UBERON:0000074	90.00	gold quality
nephron tubule	UBERON:0001231	89.91	gold quality
small intestine	UBERON:0002108	89.70	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	89.33	gold quality
metanephric glomerulus	UBERON:0004736	89.06	gold quality
rectum	UBERON:0001052	88.60	gold quality
visceral pleura	UBERON:0002401	88.40	gold quality
pituitary gland	UBERON:0000007	88.05	gold quality
kidney epithelium	UBERON:0004819	87.83	gold quality
inferior olivary complex	UBERON:0002127	87.41	silver quality
left adrenal gland	UBERON:0001234	87.19	gold quality
adenohypophysis	UBERON:0002196	86.99	gold quality
right adrenal gland	UBERON:0001233	86.85	gold quality
transverse colon	UBERON:0001157	86.80	gold quality
right adrenal gland cortex	UBERON:0035827	86.73	gold quality
left adrenal gland cortex	UBERON:0035825	86.59	gold quality
Brodmann (1909) area 23	UBERON:0013554	86.47	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.12	gold quality
adrenal gland	UBERON:0002369	85.81	gold quality
spleen	UBERON:0002106	85.72	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.17
E-MTAB-6075	no	235.30

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

131 targeting SLC46A3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-9718	99.94	68.91	918
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-219A-5P	99.91	73.36	735
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-302A-3P	99.89	71.23	1777
HSA-MIR-302B-3P	99.89	71.23	1777
HSA-MIR-302C-3P	99.89	71.20	1778

Literature-anchored findings (GeneRIF, showing 1)

• our results establish SLC46A3 as a direct transporter of maytansine-based catabolites from the lysosome to the cytoplasm (PMID:26631267)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc46a3	ENSDARG00000077313
danio_rerio	SLC46A3	ENSDARG00000079933
mus_musculus	Slc46a3	ENSMUSG00000029650
rattus_norvegicus	Slc46a3	ENSRNOG00000000937

Paralogs (2): SLC46A1 (ENSG00000076351), SLC46A2 (ENSG00000119457)

Protein

Protein identifiers

Lysosomal proton-coupled steroid conjugate and bile acid symporter SLC46A3 — Q7Z3Q1 (reviewed: Q7Z3Q1)

Alternative names: Solute carrier family 46 member 3

All UniProt accessions (1): Q7Z3Q1

UniProt curated annotations — full annotation on UniProt →

Function. Lysosomal proton-coupled steroid conjugate and bile acid transporter. Preferentially recognizes lipophilic steroid conjugates or bile acis as endogenous substrates and seems to mediate escape from lysosomes to the cytoplasm. Modulates hepatic cytosolic copper homeostasis, maybe acting as a lysosomal copper transporter and sequestering copper ions in the lysosome. Transports catabolites of non-cleavable antibody-drug conjugates from the lysosome to the cytoplasm. Delivers pathogen-associated molecular patterns to cytosolic pattern recognition receptors as part of the innate immune response to microbes. Selectively transports bacterial muramyl dipeptide (MDP) into the cytosol for recognition by NOD2, triggering inflammatory responses. Likely acts as a redundant importer of cyclic GMP-AMP dinucleotides (cGAMPs) in monocyte and macrophage cell lineages. The transport mechanism, its electrogenicity and stoichiometry remain to be elucidated.

Subcellular location. Lysosome membrane.

Similarity. Belongs to the major facilitator superfamily. SLC46A family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q7Z3Q1-1	1	yes
Q7Z3Q1-2	2
Q7Z3Q1-3	3

RefSeq proteins (3): NP_001129391, NP_001334889, NP_861450* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011701	MFS	Family
IPR036259	MFS_trans_sf	Homologous_superfamily

Pfam: PF07690

Catalyzed reactions (Rhea), 8 shown:

• estrone 3-sulfate(out) + n H(+)(out) = estrone 3-sulfate(in) + n H(+)(in) (RHEA:75483)
• dehydroepiandrosterone 3-sulfate(out) + n H(+)(out) = dehydroepiandrosterone 3-sulfate(in) + n H(+)(in) (RHEA:75487)
• 25-hydroxyvitamin D3 sulfate(out) + n H(+)(out) = 25-hydroxyvitamin D3 sulfate(in) + n H(+)(in) (RHEA:75491)
• cholate(out) + n H(+)(out) = cholate(in) + n H(+)(in) (RHEA:75499)
• glycocholate(out) + n H(+)(out) = glycocholate(in) + n H(+)(in) (RHEA:75503)
• taurocholate(out) + n H(+)(out) = taurocholate(in) + n H(+)(in) (RHEA:75507)
• N-acetyl-D-muramoyl-L-alanyl-D-isoglutamine(out) + n H(+)(out) = N-acetyl-D-muramoyl-L-alanyl-D-isoglutamine(in) + n H(+)(in) (RHEA:76371)
• 2’,3’-cGAMP(out) + n H(+)(out) = 2’,3’-cGAMP(in) + n H(+)(in) (RHEA:76411)

UniProt features (35 total): topological domain 12, transmembrane region 11, sequence conflict 4, glycosylation site 3, splice variant 2, signal peptide 1, chain 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z3Q1-F1	86.84	0.65

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (3): 38, 46, 53

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 258 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, GSE45365_NK_CELL_VS_CD8A_DC_UP, AAGCAAT_MIR137, MULLIGHAN_NPM1_SIGNATURE_3_UP, MCLACHLAN_DENTAL_CARIES_UP, BASSO_B_LYMPHOCYTE_NETWORK, GOCC_VACUOLAR_MEMBRANE, GOBP_TRANSITION_METAL_ION_TRANSPORT, GOZGIT_ESR1_TARGETS_DN, MORF_RAD51L3, GOBP_COPPER_ION_TRANSPORT, GOBP_MONOATOMIC_CATION_TRANSPORT, MORF_CTSB, MORF_IL4, MORF_PRKCA

GO Biological Process (4): vacuolar transmembrane transport (GO:0034486), cellular response to 2,3,7,8-tetrachlorodibenzodioxine (GO:1904613), copper ion transmembrane transport (GO:0035434), transmembrane transport (GO:0055085)

GO Molecular Function (4): copper ion transmembrane transporter activity (GO:0005375), symporter activity (GO:0015293), transmembrane transporter activity (GO:0022857), protein binding (GO:0005515)

GO Cellular Component (4): lysosomal membrane (GO:0005765), extracellular exosome (GO:0070062), lysosome (GO:0005764), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transmembrane transport	2
cellular response to chemical stimulus	1
response to 2,3,7,8-tetrachlorodibenzodioxine	1
copper ion transport	1
monoatomic cation transmembrane transport	1
transport	1
cellular process	1
copper ion transmembrane transport	1
transition metal ion transmembrane transporter activity	1
secondary active transmembrane transporter activity	1
transporter activity	1
binding	1
lysosome	1
lytic vacuole membrane	1
extracellular vesicle	1
lytic vacuole	1
cellular anatomical structure	1

Protein interactions and networks

STRING

490 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC46A3	FAM117A	Q9C073	385
SLC46A3	SLC67A2	Q8NBP5	373
SLC46A3	CPPED1	Q9BRF8	370
SLC46A3	SLC33A2	Q96ES6	350
SLC46A3	HDHD3	Q9BSH5	327
SLC46A3	SLC61A1	Q6N075	323
SLC46A3	SLC29A3	Q9BZD2	320
SLC46A3	SLC75A1	Q14728	314
SLC46A3	SLC26A1	Q9H2B4	305
SLC46A3	PITRM1	Q5JRX3	300
SLC46A3	RBP5	P82980	284
SLC46A3	SIDT2	Q8NBJ9	280
SLC46A3	TLCD5	Q6ZRR5	272
SLC46A3	GMFG	O60234	267
SLC46A3	WDR91	A4D1P6	263

IntAct

3 interactions, top by confidence:

A	B	Type	Score
SLC46A3	rep	psi-mi:“MI:0915”(physical association)	0.370
SLC46A3	CLGN	psi-mi:“MI:0914”(association)	0.350

BioGRID (47): LGALS3 (Affinity Capture-MS), SLC46A3 (Two-hybrid), SLC46A3 (Two-hybrid), SLC46A3 (Co-fractionation), THOP1 (Co-fractionation), ABCA3 (Affinity Capture-MS), ABCB1 (Affinity Capture-MS), ACAD11 (Affinity Capture-MS), ATG9A (Affinity Capture-MS), CANX (Affinity Capture-MS), CDC42SE2 (Affinity Capture-MS), CLGN (Affinity Capture-MS), CXCL16 (Affinity Capture-MS), CYB5B (Affinity Capture-MS), FBXO21 (Affinity Capture-MS)

ESM2 similar proteins: A0A0R4ILB2, A0A8M9Q308, A1A4N1, A2CER7, A5D7V7, A8WGF7, B0S5Y3, B2RXV4, B5X4H8, O00400, O00476, O01735, O23596, P30638, P36836, P46029, P60815, Q11073, Q16348, Q28722, Q28FF3, Q503P5, Q5F4B8, Q5RBM3, Q5XGK0, Q63424, Q6AYY8, Q6DDL7, Q6DIT7, Q6GMG6, Q6PB15, Q7Z3Q1, Q84XI3, Q86WB7, Q91X85, Q944P0, Q99808, Q99J27, Q9BZD2, Q9C8X2

Diamond homologs: A5D7V7, F1NJ67, Q05B81, Q5BK75, Q5EBA8, Q5F4B8, Q5RBM3, Q6DCX5, Q6PEM8, Q7Z3Q1, Q7ZWG6, Q96NT5, Q9DC26, P02980, Q8NBP5, Q9D2V8, C5BC70, P45123

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

74 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	66
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1353 predictions. Top by Δscore:

Variant	Effect	Δscore
13:28701577:CAACA:C	acceptor_gain	1.0000
13:28701578:AACA:A	acceptor_gain	1.0000
13:28701579:ACA:A	acceptor_gain	1.0000
13:28701580:CA:C	acceptor_gain	1.0000
13:28701580:CACTA:C	acceptor_gain	1.0000
13:28701581:AC:A	acceptor_loss	1.0000
13:28701582:C:CC	acceptor_gain	1.0000
13:28701582:C:G	acceptor_loss	1.0000
13:28701583:T:C	acceptor_loss	1.0000
13:28701584:A:C	acceptor_gain	1.0000
13:28701579:ACACT:A	acceptor_gain	0.9900
13:28701580:CACT:C	acceptor_gain	0.9900
13:28701581:ACTAT:A	acceptor_gain	0.9900
13:28701582:CTAT:C	acceptor_gain	0.9900
13:28701584:A:AC	acceptor_gain	0.9900
13:28703937:ACAT:A	donor_loss	0.9900
13:28703938:CAT:C	donor_loss	0.9900
13:28703939:ATA:A	donor_loss	0.9900
13:28703940:TA:T	donor_loss	0.9900
13:28710840:CTGG:C	acceptor_gain	0.9900
13:28712075:T:A	donor_gain	0.9900
13:28712774:CA:C	acceptor_gain	0.9900
13:28712775:A:C	acceptor_gain	0.9900
13:28713085:C:CT	acceptor_gain	0.9900
13:28713085:C:T	acceptor_gain	0.9900
13:28713086:G:T	acceptor_gain	0.9900
13:28718494:AC:A	donor_gain	0.9900
13:28718494:ACC:A	donor_gain	0.9900
13:28718495:CC:C	donor_gain	0.9900
13:28718495:CCC:C	donor_gain	0.9900

AlphaMissense

3008 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
13:28712807:A:C	S311R	0.996
13:28712807:A:T	S311R	0.996
13:28712809:T:G	S311R	0.996
13:28712864:C:A	W292C	0.985
13:28712864:C:G	W292C	0.985
13:28712866:A:G	W292R	0.985
13:28712866:A:T	W292R	0.985
13:28713211:C:G	G177R	0.983
13:28713211:C:T	G177R	0.983
13:28712749:C:G	G331R	0.977
13:28712749:C:T	G331R	0.977
13:28713231:G:T	A170D	0.977
13:28713455:A:C	S95R	0.977
13:28713455:A:T	S95R	0.977
13:28713457:T:G	S95R	0.977
13:28712748:C:T	G331E	0.976
13:28713295:C:G	G149R	0.974
13:28713295:C:T	G149R	0.974
13:28712835:G:T	A302D	0.972
13:28713210:C:T	G177E	0.972
13:28713503:A:C	S79R	0.971
13:28713503:A:T	S79R	0.971
13:28713505:T:G	S79R	0.971
13:28704089:A:C	F385L	0.968
13:28704089:A:T	F385L	0.968
13:28704091:A:G	F385L	0.968
13:28712749:C:A	G331W	0.968
13:28713237:C:G	R168P	0.968
13:28713289:A:G	C151R	0.968
13:28713315:C:A	G142V	0.968

dbSNP variants (sampled 300 via entrez): RS1000007679 (13:28704488 C>T), RS1000212230 (13:28714915 A>G), RS1000304951 (13:28717458 C>T), RS1000337639 (13:28707120 G>A), RS1000369886 (13:28718517 C>T), RS1000599367 (13:28706842 A>G), RS1000814651 (13:28716385 G>A), RS1000954712 (13:28713934 A>G), RS1001132555 (13:28704939 G>A,C), RS1001184583 (13:28716597 G>A), RS1001339619 (13:28708603 CTTTTT>C), RS1001587963 (13:28718791 G>A), RS1001601083 (13:28708206 G>T), RS1001659684 (13:28718580 C>T), RS1001791307 (13:28712309 T>C)

Disease associations

OMIM: gene MIM:616764 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST000765_1	Non-alcoholic fatty liver disease histology (other)	9.000000e-06
GCST001762_294	Obesity-related traits	1.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0003939	energy intake

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC46 family of folate transporters

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, affects cotreatment, increases expression	8
Silicon Dioxide	decreases expression, increases expression	3
potassium chromate(VI)	affects cotreatment, decreases expression	2
Benzo(a)pyrene	affects methylation, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
bisphenol F	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
ethyl-p-hydroxybenzoate	increases expression	1
trichostatin A	increases expression	1
sodium arsenite	increases expression	1
nickel sulfate	increases expression	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects response to substance	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Zoledronic Acid	increases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression	1

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4VZ	LS180-SLC46A3-KO-c1	Cancer cell line	Female
CVCL_D4W0	LS180-SLC46A3-KO-c5	Cancer cell line	Female
CVCL_TN82	HAP1 SLC46A3 (-) 1	Cancer cell line	Male
CVCL_TN83	HAP1 SLC46A3 (-) 2	Cancer cell line	Male
CVCL_TN84	HAP1 SLC46A3 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer